MedTrace Logo

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

NCT01562041 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-06-18

Study results available
· View outcomes & findings →

Summary

The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

Conditions

  • Atherosclerotic Coronary Vascular Disease

Interventions

DRUG

Ranolazine 500 mg

Ranolazine 500 mg, oral tablet, b.i.d.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-09
Primary Completion
2014-01-02
Completion
2014-01-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01562041 on ClinicalTrials.gov